Craft

Advanced
Eutilex

Eutilex

Stock Price

₩2.9 K

2023-09-26

Market Capitalization

₩21.7 B

2023-09-26

Revenue

₩215.7 M

FY, 2022

Eutilex Summary

Company Summary

Overview
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy. Additionally, it offers antibody therapeutics based on its proprietary immunotherapy technology.
Type
Public
Status
Active
Founded
2015
HQ
KR | view all locations
Website
http://eutilex.com/en/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Byoung S. Kwon

    Byoung S. Kwon, CEO

    • Soo Young Choi

      Soo Young Choi, COO

      • Edwin E. Kwon

        Edwin E. Kwon, CFO

        • Jeonghoon Han

          Jeonghoon Han, CBO

          LocationsView all

          1 location detected

          • Seoul HQ

            Korea (Republic of)

            25 Gasan digital 1-ro, Geumcheon-gu

          Eutilex Financials

          Summary Financials

          Revenue (Q1, 2023)
          ₩37.7M
          Gross profit (Q1, 2023)
          (₩7.9B)
          Net income (Q1, 2023)
          (₩7.5B)
          Cash (Q1, 2023)
          ₩35.7B
          EBIT (Q1, 2023)
          (₩7.9B)
          Enterprise value
          ($2.9B)

          Competitors and Similar Companies

          Compare competitors

          News

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2023
          Share price data provided by IEX